The price of Ginkgo Bioworks Holdings Inc (NYSE: DNA) closed at $1.08 in the last session, up 0.93% from day before closing price of $1.07. In other words, the price has increased by $+0.0100 from its previous closing price. On the day, 16074900 shares were traded.
Ratios:
We take a closer look at DNA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.11 and its Current Ratio is at 6.11. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.20.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Raymond James on November 14, 2023, Downgraded its rating to Mkt Perform and sets its target price to $2.50 from $3.50 previously.
Goldman Downgraded its Neutral to Sell on June 02, 2023, whereas the target price for the stock was revised from $3 to $1.25.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 02 ’24 when Dmytruk Mark E. sold 51,169 shares for $1.05 per share. The transaction valued at 53,727 led to the insider holds 865,079 shares of the business.
Dmytruk Mark E. sold 38,826 shares of DNA for $48,765 on Mar 04 ’24. The insider now owns 808,125 shares after completing the transaction at $1.26 per share. On Feb 02 ’24, another insider, Dmytruk Mark E., who serves as the insider of the company, sold 39,569 shares for $1.21 each. As a result, the insider received 47,799 and left with 761,737 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNA now has a Market Capitalization of 2.32B and an Enterprise Value of 1.62B. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.73 while its Price-to-Book (P/B) ratio in mrq is 1.85. Its current Enterprise Value per Revenue stands at 6.45 whereas that against EBITDA is -1.98.
Stock Price History:
Over the past 52 weeks, DNA has reached a high of $2.55, while it has fallen to a 52-week low of $1.03. The 50-Day Moving Average of the stock is 1.2486, while the 200-Day Moving Average is calculated to be 1.6028.
Shares Statistics:
According to the various share statistics, DNA traded on average about 22.49M shares per day over the past 3-months and 17.18M shares per day over the past 10 days. A total of 1.53B shares are outstanding, with a floating share count of 1.34B. Insiders hold about 33.94% of the company’s shares, while institutions hold 58.53% stake in the company. Shares short for DNA as of Mar 15, 2024 were 262.24M with a Short Ratio of 11.66, compared to 250.23M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 12.18% and a Short% of Float of 19.31%.
Earnings Estimates
The company has 6 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.08 for the current quarter, with a high estimate of -$0.08 and a low estimate of -$0.1, while EPS last year was -$0.11. The consensus estimate for the next quarter is -$0.08, with high estimates of -$0.07 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.28 and -$0.38 for the fiscal current year, implying an average EPS of -$0.32. EPS for the following year is -$0.27, with 6 analysts recommending between -$0.21 and -$0.36.
Revenue Estimates
According to 6 analysts, the current quarter’s revenue is expected to be $46.43M. It ranges from a high estimate of $49.93M to a low estimate of $43M. As of the current estimate, Ginkgo Bioworks Holdings Inc’s year-ago sales were $80.7M, an estimated decrease of -42.50% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $53.28M, a decrease of -33.90% over than the figure of -$42.50% in the same quarter last year. There is a high estimate of $57.83M for the next quarter, whereas the lowest estimate is $50.5M.
A total of 7 analysts have provided revenue estimates for DNA’s current fiscal year. The highest revenue estimate was $226.92M, while the lowest revenue estimate was $217.45M, resulting in an average revenue estimate of $223.54M. In the same quarter a year ago, actual revenue was $251.46M, down -11.10% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $310.21M in the next fiscal year. The high estimate is $398.3M and the low estimate is $284.19M. The average revenue growth estimate for next year is up 38.80% from the average revenue estimate for this year.
